PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20645940-7	2011	CONCLUSION: Vitamin E and enoxaparin are able not only to prevent foetal wastage but also to balance IL-6 and VEGF placental levels, presenting a new potential therapeutic alternative for patients with recurrent abortion not associated with thrombophilias.	Enoxaparin	26-36	vascular endothelial growth factor A	Homo sapiens	110-114	
22038446-8	2012	Mean overall VEGF serum concentration was higher in patients with enoxaparin.	Enoxaparin	66-76	vascular endothelial growth factor A	Homo sapiens	13-17	
17920287-5	2007	VEGF(165) significantly decreased during both enoxaparin (chi(2) ANOVA=33.0, P<10(-6)) and UFH (chi(2) ANOVA=27.2, P<10(-6)) anticoagulated HD, while over-HD bFGF remained stable regardless of the type of heparin.	Enoxaparin	46-56	vascular endothelial growth factor A	Homo sapiens	0-4	
17920287-8	2007	CONCLUSION: The traditional UFH regimen, in contrast to enoxaparin treatment, is connected with dose-depended VEGF(165) decrease during HD procedure.	Enoxaparin	56-66	vascular endothelial growth factor A	Homo sapiens	110-114	
17692905-8	2008	Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH.	Enoxaparin	98-108	vascular endothelial growth factor A	Homo sapiens	50-54	
17920287-6	2007	The switch from enoxaparin to UFH treatment was connected with 34% VEGF(165) decrease after 180min of HD and had no impact on bFGF.	Enoxaparin	16-26	vascular endothelial growth factor A	Homo sapiens	67-71